



PHARMACEUTICAL 2022









PHARMACEUTICAL 2022

Merck & Co. Inc. Rank 18 of 475



The relative strengths and weaknesses of Merck & Co. Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck & Co. Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 377% points. The greatest weakness of Merck & Co. Inc. is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 68% points.

The company's Economic Capital Ratio, given in the ranking table, is 226%, being 503% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	30,266,000
Cost of Goods Sold	13,626,000
Intangible Assets	44,197,000
Liabilities, Current	23,872,000
Liabilities, Non-Current	0
Other Assets	11,952,000
Other Compr. Net Income	1,756,000
Other Expenses	854,000
Other Liabilities	0
Other Net Income	704,000
Property and Equipment	19,279,000
Research and Development	12,245,000
Revenues	48,704,000
Selling, General and Administrative Expense	9,634,000

Output Variable	Value in 1000 USD
Assets	105,694,000
Liabilities	23,872,000
Expenses	36,359,000
Stockholders Equity	81,822,000
Net Income	13,049,000
Comprehensive Net Income	13,927,000
Economic Capital Ratio	226%

